Research
Hormonal
CagriSema is being marketed as a safe and potentially superior medication to lower both Hemoglobin A1c and body weight.
Practitioners may consider CagriSema as a treatment option for patients needing glycemic control and weight management.
StrongSupportsmedium confidence
This drug is being marketed as a safe and potentially superior medication to lower both Hemoglobin A1c and body weight.
Why this rating
The claim is based on the investigation of a new drug, indicating a high level of research backing.
Source
Advancing Diabetes Management and Glycemic Control While Exploring CagriSema’s Impact on Obesity Management
Somar Hadid et al. · Cardiology in Review · 2025
DOI 10.1097/crd.0000000000000940
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →